anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
TREXIMET contains an NSAID. NSAID-containing products can cause serious gastrointestinal adverse events including inflammation, bleeding, ulceration, and perforation of the stomach, small intestine, or large intestine, which can be fatal.

These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDs. Only 1 in 5 patients who develop a serious upper gastrointestinal adverse event on NSAID therapy is symptomatic. Upper gastrointestinal ulcers, gross bleeding, or perforation caused by NSAIDs appear to occur in approximately 1% of patients treated daily for 3 to 6 months and in about 2% to 4% of patients treated for 1 year. These trends continue with longer duration of use, increasing the likelihood of developing a serious gastrointestinal event at some time during the course of therapy. However, even short-term therapy is not without risk. Among 3,302 patients with migraine who received TREXIMET in premarketing controlled and uncontrolled clinical trials, 1 patient experienced a recurrence of gastric ulcer after taking 8 doses over 3 weeks, and 1 patient developed a gastric ulcer after treating an average of 8 attacks per month over 7 months. 

NSAID-containing products, including TREXIMET, should be prescribed with extreme caution in those with a prior history of ulcer disease or gastrointestinal bleeding. Patients with a prior history of peptic ulcer disease and/or gastrointestinal bleeding who use NSAIDs have a greater than 10-fold increased risk for developing gastrointestinal bleeding compared to patients with neither of these risk factors. Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. Most spontaneous reports of fatal gastrointestinal events are in elderly or debilitated patients, and therefore special care should be taken in treating this population.

To minimize the potential risk for an adverse gastrointestinal event in patients treated with an NSAID-containing product, the lowest effective dose should be used for the shortest possible duration. Patients and physicians should remain alert for signs and symptoms of gastrointestinal ulceration and bleeding during NSAID therapy and promptly initiate additional evaluation and treatment if a serious gastrointestinal adverse event is suspected. This should include discontinuation of the NSAID until a serious gastrointestinal adverse event is ruled out. For high-risk patients, alternate therapies that do not involve NSAIDs should be considered.

NSAIDs should be given with care to patients with a history of inflammatory bowel disease (ulcerative colitis, Crohn's disease) as their condition may be exacerbated.
Hyperuricemia (HUA) has attained a considerable global health concern, related to the development of other metabolic syndromes. Xanthine oxidase (XO), the main enzyme that catalyzes xanthine and hypoxanthine into uric acid (UA), is a key target for drug development against HUA and gout. Available XO inhibitors are effective, but they come with side effects. Recent, research has identified new XO inhibitors from dietary sources such as flavonoids, phenolic acids, stilbenes, alkaloids, polysaccharides, and polypeptides, effectively reducing UA levels. Structural activity studies revealed that -OH groups and their substitutions on the benzene ring of flavonoids, polyphenols, and stilbenes, cyclic rings in alkaloids, and the helical structure of polysaccharides are crucial for XO inhibition. Polypeptide molecular weight, amino acid sequence, hydrophobicity, and binding mode, also play a significant role in XO inhibition. Molecular docking studies show these bioactive components prevent UA formation by interacting with XO substrates via hydrophobic, hydrogen bonds, and π-π interactions. This review explores the potential bioactive substances from dietary resources with XO inhibitory, and UA lowering potentials detailing the molecular mechanisms involved. It also discusses strategies for designing XO inhibitors and assisting pharmaceutical companies in developing safe and effective treatments for HUA and gout.
PURPOSE:To obtain a cataplasm having no supporting body, having undefined shape, capable of using by adjusting to size of affected part, having good adhesion with a bending part and sustaining cool feeling effect, by containing a specific amount of acrylic resin. CONSTITUTION:The aimed cataplasm contains 10-30wt.%, preferably 15-25wt.% acrylic resin (e.g. polymer or copolymer such as methyl polymethacrylate or ethyl polymethacrylate). The above-mentioned cataplasm is preferably obtained by uniformly blending the above-mentioned resin with an ingredient having the effect of medicine using 30-60wt.% organic solvent (e.g. methanol, ethanol or isopropanol), 1-6wt.% water (purified water), 3-10wt.% plasticizer (e.g. dibutyl phthalate), etc. and forming the blend into paste or aerosol agent.
BACKGROUND: Cardiogenic shock (CS) is the leading cause of death in patients with myocardial infarction with a mortality rate greater than 50%. Recently, the CS 4 Proteins (CS4P) and CLIP scores have been developed to predict survival in CS patients. However, their impact in acute CS and additional short-term left ventricular (LV) circulatory support as prognostic markers is currently not known.
METHODS AND RESULTS: CS was induced in a porcine model by injecting microsphere particles into the left main coronary artery. Mechanical circulatory support was performed by additional percutaneous LV unloading using an Impella microaxial flow-pump for 30 minutes. Serum samples were collected at baseline, following the onset of CS, and additional LV unloading. Serum levels of biomarkers of the CS4P (beta-2-microglobulin, ALDOB, L-FABP, SerpinG1) and the CLIP scores (Cystatin C, Lactate, Interleukin-6, NT-proBNP) were neither different at any time point investigated nor did they correlate with cardiac output.
CONCLUSION: The CS4P and CLIP scores do not reflect immediate whole-body dysregulation in acute CS and have not been able to predict the potential reversal following additional short-term mechanical support by LV unloading in our experimental model. The impact of both scores as prognostic markers after the immediate onset of CS and following additional short-term LV unloading to identify patients at greatest risk remains to be determined.
BACKGROUND: Nocturia, the most common lower urinary tract symptom (LUTS), significantly impacts socioeconomic factors and individuals' quality of life and is closely related to many diseases. This study utilized data from NHANES 2005-2010 to explore the relationship between family income to poverty ratio (PIR) and the presence of nocturia symptoms in adults aged 20 or older in the United States.
METHODS: Data from the National Health and Nutrition Examination Survey (NHANES) in 2005-2010, including 6,662 adults aged 20 or older, were utilized for this cross-sectional study. The baseline data was used to display the distribution of each characteristic visually. Multiple linear regression and smooth curve fitting were used to study the linear and non-linear correlations between PIR and nocturia. Subgroup analysis and interaction tests were conducted to examine the stability of intergroup relationships.
RESULTS: Out of the 6,662 adult participants aged 20 or older, 1,300 households were categorized as living in poverty, 3,671 households had a moderate income, and 1,691 households were classified as affluent. Among these participants, 3,139 individuals experienced nocturia, representing 47.12% of the total, while 3,523 individuals were nocturia-free, constituting 52.88% of the total population. After adjusting for all other covariates, it was found that PIR was significantly negatively correlated with nocturia (OR: 0.875, 95%CI: 0.836-0.916 P<0.0001). This trend persisted when PIR was divided into three groups (PIR <1, PIR 1-4, PIR > 4) or quartiles. There was a non-linear negative correlation between PIR and nocturia.
CONCLUSION: Our findings indicated that lower PlR was associated with a higher risk of nocturia in adults aged 20 or older in the United States. These findings highlight the importance of considering socioeconomic factors in preventing and managing nocturia. Nonetheless, further exploration of the causal nexus between these factors was precluded due to the constraints of a cross-sectional design.
<P>PROBLEM TO BE SOLVED: To provide a skin-beautifying agent in which vitamin Ks is combined with vitamin E, capable of restoring the skin having symptom such as liver spot of face, dark circles under one's eyes, blush or burning sensation to the normal skin by using routinely used cosmetic without carrying out administration of a medicine or operation.  <P>SOLUTION: The symptom such as liver spot of face, dark circles under one's eyes, blush or burning sensation appears near blood capillary by stress, fatigue and influence of ultraviolet light. The symptom is caused by a proteolytic enzyme and generated by blood stasis or bleeding of the blood capillary. The blood capillary is required to be tightened and restored to a blood capillary having elasticity and congestion is relieved and a proteolytic enzyme inhibitor of fibroblast is produced in a large amount in order to eliminate these symptoms. Therefore, vitamin Ks and vitamin E are formulated in skin lotion, milky lotion or foundation.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
BACKGROUND: Pitt-Hopkins syndrome (PTHS) is a rare neurodevelopmental disorder that results from variants of TCF4 gene. PTHS follows an autosomal dominant inheritance pattern and the underlying pathological mechanisms of this disease are still unclear.
METHODS: Whole-genome sequencing (WGS) was conducted to screen for potential pathogenic variant in a boy highly suspected of having a genetic disorder. PCR and Sanger sequencing were used to verify the effects of the variant. Serum TCF4 levels were measured by ELISA.
RESULTS: We present a 4-year and 3-month-old Chinese boy clinically and molecularly diagnosed with PTHS. The proband experienced global development delay, and the preliminary clinical diagnosis was cerebral palsy. WGS identified a de novo heterozygous variant: c.*1A > G in the 3'UTR of the TCF4 gene as a potential cause of his condition. The variant was verified to cause aberrant mRNA splicing by PCR and the aberrant splicing was confirmed by Sanger sequencing.
CONCLUSION: The study identified and demonstrated the pathogenicity of a novel 3'UTR site TCF4 variant for the first time. This research enhances understanding of pathogenetic mechanisms of PTHS and aids genetic counseling and diagnosis.
Idiopathic normal pressure hydrocephalus (iNPH) is a clinical condition characterized by symptoms of gait disturbance, cognitive dysfunction, and urinary disturbance. In contrast, progressive supranuclear palsy (PSP) is a progressive neurodegenerative disease characterized by supranuclear gaze palsy, akinetic rigidity, gait disturbance, and dementia. PSP manifests various clinical phenotypes that mimic other diseases and occasionally present iNPH-like presentations. Our previous publication showed that PSP develops iNPH-like magnetic resonance imaging (MRI) features more frequently than other neurodegenerative diseases. It is thus sometimes challenging to distinguish iNPH from PSP. Recently, we showed that patients with PSP, particularly those with iNPH-like MRI findings, often demonstrate amelioration of their gait disturbance following a spinal tap or shunt operation. Moreover, our study revealed that both patients with iNPH and PSP often manifest a placebo effect that can be evaluated by implementing a sham spinal tap. Therefore, although a positive response to a spinal tap has been thought of as a distinct feature of iNPH, it may not be useful in differentiating iNPH and PSP. However, in clinical practice, comparing the response to a spinal tap with that of a sham spinal tap may help accurately specify patients with iNPH or PSP who definitively respond to the shunt operation.
Following randomization into two groups, the intervention NICUs (n = 12) will receive training in the EPIQ method and then develop, implement, and document evidence-based practice changes to reduce hospital-acquired infection. Compliance with practice changes and neonatal outcomes will be monitored. NICUs will receive quarterly feedback on their progress, as well as access to implementation support. Control NICUs (n = 12) will collect neonatal data and continue to provide standard care. Study subjects will be all preterm infants born at \<34 weeks' gestation and admitted to participating NICUs during the trial (estimated n = 5,200 per year). Data analysis will be conducted to compare neonatal outcomes and health-care resources used between the intervention and control groups.
The project have 2 separate aims: AI-SEE images: To make SE reading operator-independent for each of the essential reading steps (from A to E). AI-SEE data: To identify the links between clinical imaging and stress variables and develop a tailored personalized model for risk prediction. For each parameter assessment (positivity versus negativity), the area under the receiver-operating characteristic curve produced by the deep learning algorithm will be compared to that produced by the experienced cardiologist (cross-sectional analysis). AI-SEE images: a set of images from 1 250 patients from at least 10 laboratories will be sufficient to develop the algorithm (modeling set) subsequently prospectively tested on a different set of 1250 patients (validation set). AI-SEE data: a set of data from 2 500 patients from at least 10 laboratories will be sufficient to develop the algorithm (modeling set) subsequently tested on a different set of 2 500 patients (validation set).
Lymphotoxin α and lymphotoxin β (LTs), TNF superfamily members, are expressed in either soluble (LTα3) or membrane-bound (LTα1β2 or LTα2β1) forms. In the pathological context, LT-mediated signaling is known to exacerbate autoimmunity by perpetuating inflammation and promoting the formation of tertiary lymphoid organs. Despite this understanding, the exact roles of LTα and LTβ in the pathogenesis of the murine model of multiple sclerosis, and experimental autoimmune encephalomyelitis (EAE), remain controversial. Here, we employed a panel of gene-modified mice with cell-type restricted ablation of LTα (targeting both membrane-bound and soluble forms of LTs) to unravel the contributions of LTs from various lymphoid cells, namely T cells, type 3 innate lymphoid cells (ILC3) and B cells, in EAE. We found that the effects of LTα deletion were dependent on the cellular source. ILC3-derived lymphotoxins exerted a protective role in EAE by regulating the accumulation of IFN-ɣ- and GM-CSF-producing TH cells in the CNS. In contrast, T-cell-derived lymphotoxins promoted IL-17A- and GM-CSF-mediated TH responses in the periphery, whereas B-cell-derived lymphotoxins were pathogenic only in the autoantibody-mediated EAE model. Collectively, our findings unveil the multifaceted involvement of lymphotoxins in EAE pathogenesis and challenge the view that lymphotoxins play a solely pathogenic role in neuroinflammation.
Investigators plan a prospective cohort study with an adaptive design based on physical function status. The design will involve tracking the number of women recruited with physical function impairment and those without any functional impairment. Investigators aim to recruit similar numbers of women in each group. If they find unequal numbers, they will adapt recruit strategies based on a woman's functional status.

Investigators will compare changes in outcome measures within and between groups after 6 and 12 weeks of pelvic floor muscle exercises (PFME). The change in pelvic floor strength/efficiency will be assessed by repeating the pelvic floor PERFECT assessment and will be compared between groups. Changes in UI symptoms, symptom severity, and impact of UI symptoms on quality of life will be determined using standardized measures described above. Data analysis will define associations between changes in PERFECT measures and the change in UI episodes (based on 3-day voiding diary), severity, and type (based on QUID-7), and impact on quality of life (PFIQ-7) within and between groups. Objective measurement of lower-extremity strength will inform the relationship between lower-extremity strength, pelvic floor strength, and UI symptoms at baseline and the 6-week visit.
PURPOSE:To provide a hair cosmetic giving moderate style-keeping property and comfortable feeling to the hair, and containing a component obtained by extracting a vegetable with a polar solvent, and silk fiber or hydrolyzed silk. CONSTITUTION:The objective hair cosmetic contains (A) 0.01-1.0wt% (in terms of solid) of a component obtained by extracting a vegetable (e.g. birch, rosemarry, arnica, sage, etc.) with a polar solvent and (B) 0.1-5.0wt% of silk fiber or hydrolyzed silk. The ratio of the vegetable extract to the silk fiber, etc. is 1-8. The silk fiber may be used in the form of fine powder of the fiber itself or the fiber treated with an acid, however, it is preferable to use a product hydrolyzed with an acid, alkali or an enzyme. The molecular weight of the decomposed product is preferably 350-30,000.
BACKGROUND: Surgical site infection (SSI) is the most consistently reported complication of cranioplasty. No material showed a categorical superiority in the incidence of infection. Porous polyethylene (PE) is considered a low risk material regarding SSI. However, the literature data are very limited. Thus, our objective was to verify the assumed low incidence of SSI after PE cranioplasty in patients at high risk of SSI. The primary objective was the infection rate, while secondary objectives were implant exposure, revision and cosmetic results.
METHOD: Patients who underwent three-dimensional (3D) personalized PE cranioplasty in the period 2014-2023 were evaluated prospectively. Only patients with an increased risk of SSI, and a satisfactory clinical conditions were included in the study.
RESULTS: Thirty procedures were performed in 30 patients. Cranioplasty was performed 23 times after hemispheric decompressive craniectomy, five times after limited size craniotomy and two times after bifrontal decompressive craniectomy. Risk factors for the development of infection were 18 previous SSIs, 16 previous repeated revision surgeries, four intraoperatively opened frontal sinuses and two times radiotherapy. Neither infection nor implant exposure was detected in any patient. All patients were satisfied with the aesthetic result. In two cases, a revision was performed due to postoperative epidural hematoma.
CONCLUSIONS: Three-dimensional personalized PE cranioplasty is associated with an extremely low incidence of SSI even in high-risk patients. However, our conclusions can only be confirmed in larger studies.
The present invention relates to a method for preparing novel antisuppository by using short chain polypeptide containing a Lys-Gly-Asp(KGD for short) function sequence as characteristics, and the use thereof. The antisuppository is a cyclohepta-peptide molecule. A heptapeptide molecule with linear length is synthesized by a chemosynthesis method, and moreover, the cyclohepta-peptide molecule (KGD-cyclohepta-peptide for short) with a (1, 7) site covalent closed loop structure is formed a disulfide bond. The cyclohepta-peptide has a sequence of Cys-Lys-Gly-Asp-Trp-Asp-Cys, and the KGD sequence is a function sequence of the KGD sequence. The KGD sequence expresses a function conformation by a cyclized structure, performs specificity identification and combination capability with a GPIIb/IIIa receptor of a fiber proteinogen receptor on a platelet membrane and expresses strong platelet aggregation resistant activity. The antisuppository has strong thrombosis forming resistant capability and high clinical application value. The present invention is new wishful thrombosis forming resistant medicine and has wide use prospects.
PURPOSE: A single-phased aquous transparent liquid cosmetic composition is provided to softly clean and/or remove a make-up from the skin and/or eye rims. CONSTITUTION: The cosmetic composition comprises: at least one C1-C6 alkyl para-hydroxybenzoate; more than 90 wt.% of water based on the total weight of the composition; and less than 0.02 wt.% of at least one metabisulfite. The composition has a relative density from about 0.99 to about 1.01. The composition further comprises 95 to 99.9 wt.% of water based on the total weight of the composition. The metabisulfite is sodium metabisulfite and contained in the amount of 0.001 to 0.02 wt.% based on the total weight of the composition. The alkyl para-hydroxybenzoate is methyl para-hydroxy benzoate, and used with another at least one alkyl para-hydroxybenzoate and/or another preservative. The alkyl para-hydroxybenzoate content is in the range of 0.01 to 1 wt.% based on the total weight of the composition. The composition contains no monovalent C1-C3 alcohol. The composition further comprises at least one polyol selected from the group consisting of propylene glycol, butylene glycol, hexylene glycol, polyethylene glycol, glycerol, dipropylene glycol and mixtures thereof.
309,012. Weissbein, S. Jan. 2. 1928. Salves; emulsions, making.-A process for the manufacture of curative creams for external use by saponifying fats or fatty acids with alkali, insufficient for neutralisation, and in the presence of colloid protectors such as glycerine and a saponin and while saponification is proceeding, introducing into the mixture with stirring a concentrated solution of a healing salt together with a saponin until a cream-like mass is obtained. In an example 54 gms. of fat (or fatty acid) are partially saponified with 8 gms. KOH, 6 gms. of water, 10 ccs. of methyl or ethyl alcohol, and 0.01 gm. of, saponin on a water bath. Shortly before the end of the reaction there is stirred into the hot reaction mixture a heated solution of 40 gms. of " Oeynhausen " salt in 80 gms. water, admixed with 0.01 gm. of saponin and 10 gms. of glycerine. On stirring a creamy mass results which is spread out to cool. The " Osenhausen " salt is a mixture of sodium, potassium, and magnesium chlorides and sulphates, the sodium and chlorine ions predominating, together with small quantities of lithium, calcium, manganese, aluminium, iron phosphates. and arsenates. Common salt may be used instead of this mixture of salts.